Gilead Sciences’ chronic hepatitis B treatment Vemlidy with health insurance benefits
Vemlidy(generic name: Tenofovir Alafenamide Fumarate), a Gilead Sciences Korea’s(CEO Seung-Woo Lee) chronic hepatitis B treatment, will receive the national health insurance benefits from the 1st of November.
Vemlidy, a tenofovir prodrug, was approved from the Ministry of Food and Drug Safety on...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.